BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At The 25th Piper Jaffray Healthcare Conference


12/3/2013 8:03:31 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today announced it will present at the 2013 Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013 at 1:30 PM EST / 10:30 PM PST at the New York Palace Hotel.

(Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a)

During the presentation, Paul Laikind, ViaCyte's President and Chief Executive Officer, will provide a corporate overview of the Company's strategy and its development activity related to VC-01 combination product, its stem cell-derived, cell therapy product that the Company believes could transform the way patients with Type 1 diabetes manage their disease. ViaCyte is planning to file an IND and initiate clinical evaluation of the VC-01 product in patients with Type 1 diabetes around the middle of next year.

The VC-01 combination product is comprised of pancreatic progenitor cells contained in a proprietary device that is designed to be inserted under the skin. Upon implant, the product is expected to vascularize as the cells further differentiate to islet-like structures that generate insulin and other expected regulatory factors in response to blood glucose levels, essentially providing patients with a replacement for the cells lost as a result of the disease.

Dr. Laikind said, "We are very excited about the progress we have made towards a break through therapy that could transform the way patients with Type 1 diabetes manage their disease. We also believe it could be an important treatment for patients with Type 2 diabetes that use insulin to help manage their disease. We look forward to reviewing our work and describing our plans for clinical development."

About ViaCyte
ViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes. The Company's lead product is based on the production of pancreatic progenitors derived from human pluripotent stem cells. These cells are implanted in a durable and retrievable encapsulation device called the Encaptra® drug delivery system. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal for this potentially transformative diabetes product is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by CIRM and JDRF.

SOURCE ViaCyte, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES